Continuous GLP-1RA use for three years was associated with the greatest reduction in MACE risk compared with sulfonylureas, whereas interruptions and discontinuations were associated with a progressive attenuation of this protective effect, with risk estimates in some scenarios approaching those of the comparator group
In November 2023, it was approved again under the brand name Zepbound for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition
This gradual delivery minimizes peaks and dips in medication levels and supports consistent appetite control from morning through evening
The default protocol around them is
Patients experiencing gastroparesis commonly report the following debilitating symptoms: Severe nausea and vomiting: Multiple daily episodes, unable to keep down liquids, leading to dangerous dehydration requiring emergency IV fluids Extreme early satiety: Feeling full after few bites, with food stuck in throat persisting hours Chronic abdominal pain and bloating: Persistent upper abdomen distention interfering with daily activities Dangerous weight loss: Inability to consume adequate calories causing vitamin deficiencies, muscle wasting, requiring feeding tubes Blood sugar fluctuations: Unpredictable glucose with nighttime lows followed by morning highs Diagnosing requires specific testing to measure gastric emptying
Wilson, A
